Sonnet BioTherapeutics Files Q2 2025 10-Q
| Field | Detail |
|---|---|
| Company | Sonnet Biotherapeutics Holdings, Inc. |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Sonnet BioTherapeutics filed its 10-Q for Q2 2025. Check financials.
AI Summary
Sonnet BioTherapeutics Holdings, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Chanticleer Holdings, Inc., is in the pharmaceutical preparations industry. The filing details financial information and business operations for the quarter.
Why It Matters
This filing provides investors with an update on Sonnet BioTherapeutics' financial health and operational progress during the second quarter of fiscal year 2025.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Sonnet BioTherapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Sonnet BioTherapeutics Holdings, Inc. (company) — Filer
- Chanticleer Holdings, Inc. (company) — Former company name
- 20250331 (date) — Period of report
- 20250513 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the period ending March 31, 2025.
What was Sonnet BioTherapeutics Holdings, Inc. formerly known as?
The company was formerly known as Chanticleer Holdings, Inc.
What is the Standard Industrial Classification code for Sonnet BioTherapeutics Holdings, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was this 10-Q filing submitted to the SEC?
The filing date (as of date) is 20250513.
What is the company's principal business address?
The business address is 100 Overlook Center, Suite 102, Princeton, NJ 08540.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Sonnet BioTherapeutics Holdings, Inc..